Ted Jenkins | VP, Head of IR |
Ankit Mahadevia | CEO |
David Melnick | Chief Medical Officer |
Cristina Larkin | COO |
Sath Shukla | CFO |
Louise Chen | Cantor |
Ritu Baral | Cowen |
Esther Hong | Berenberg |
Kevin DeGeeter | Oppenheimer |
Good afternoon, and welcome to the Spero Therapeutics Fourth Quarter and Year-End 2021 Financial Results Conference Call. [Operator Instructions] Please be advised that this call is being recorded, and a replay will be available.
You can find information on the replay and further information related to today's announcement on the Spero Therapeutics website at www.serotherapeutics.com. At this time, I would like to turn the call over to Ted Jenkins, Vice President, Investor Relations at Spero Therapeutics. Mr.